Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Biomarkers such as kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated
lipocalin (NGAL) have been used for the early diagnosis of AKI, although with no definitive
results. The investigators explored the association between plasma aging biomakers such as
sklotho and contrast induced nephropathy in patients undergoing percutaneous coronary
intervention (PCI) with contrast injection.